MDxHealth (NASDAQ:MDXH – Get Free Report) and Renalytix (NASDAQ:RNLX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
This table compares MDxHealth and Renalytix’s net margins, return on equity and return on assets.
|Return on Equity
|Return on Assets
This is a summary of recent recommendations and price targets for MDxHealth and Renalytix, as provided by MarketBeat.com.
|Strong Buy Ratings
Earnings & Valuation
This table compares MDxHealth and Renalytix’s gross revenue, earnings per share and valuation.
|Earnings Per Share
MDxHealth has higher revenue and earnings than Renalytix. MDxHealth is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
20.2% of MDxHealth shares are owned by institutional investors. Comparatively, 7.5% of Renalytix shares are owned by institutional investors. 18.3% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MDxHealth beats Renalytix on 8 of the 12 factors compared between the two stocks.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.